Yahoo
    Canadian Sec - Free Realtime Quote CAD

    Pharmala Biotech Holdings Inc. (MDMA.CN)

    0.1750 +0.0050 (+2.94%)
    As of 11:02:23 AM EST. Market Open.
    Loading Chart for MDMA.CN
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    View More
    PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill

    PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill
    GlobeNewswire 1mo ago
    PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner

    PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
    GlobeNewswire 2mo ago
    PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

    PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
    GlobeNewswire 3mo ago
    Pharmala Biotech Holdings And 2 Other TSX Penny Stocks To Consider

    Pharmala Biotech Holdings And 2 Other TSX Penny Stocks To Consider
    Simply Wall St. 5mo ago
    PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

    PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
    GlobeNewswire 5mo ago
    PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

    PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
    GlobeNewswire 6mo ago
    PharmAla Issues Q2 Financial Statements and Grants Options

    PharmAla Issues Q2 Financial Statements and Grants Options
    GlobeNewswire 6mo ago
    PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

    PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
    GlobeNewswire 6mo ago
    Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

    Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
    GlobeNewswire 5mo ago
    Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand

    Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand
    GlobeNewswire 24d ago
    Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

    Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
    GlobeNewswire 3mo ago
    View More

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: